ADMA Biologics, Inc. Sustainability Profile
ADMA Biologics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2004, the company has established itself as a leader in the development and commercialisation of specialty biologics, particularly in the field of immunoglobulin therapies. ADMA focuses on providing innovative solutions for patients with immune deficiencies and other serious conditions, offering unique products such as its proprietary immunoglobulin, ASCENIV. This product stands out due to its high purity and specific formulation, catering to the needs of patients requiring immunotherapy. With a strong market position, ADMA Biologics has achieved significant milestones, including FDA approvals and partnerships that enhance its operational reach across North America. The company continues to drive advancements in the biologics sector, committed to improving patient outcomes through its specialised therapies.
DitchCarbon Score
How does ADMA Biologics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ADMA Biologics, Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ADMA Biologics, Inc.'s reported carbon emissions
ADMA Biologics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a result, ADMA Biologics, Inc. does not appear to have established any formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. The lack of emissions data and reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. However, without specific commitments or data from ADMA Biologics, it is unclear how they plan to address climate change and carbon emissions in the future.
How Carbon Intensive is ADMA Biologics, Inc.'s Industry?
How Carbon Intensive is ADMA Biologics, Inc.'s Location?
ADMA Biologics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ADMA Biologics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
